Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
Wednesday, January 28, 2009 - 14:56
in Health & Medicine
Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.